Evaluation of Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis (dcSSc)

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 25, 2017

Primary Completion Date

April 8, 2019

Study Completion Date

November 15, 2019

Conditions

Systemic SclerosisScleroderma

Interventions

DRUG

Tofacitinib

Oral medication tofacitinib 5 mg twice a day for 24 weeks.

DRUG

Placebo Oral Tablet

Oral Placebo 5 mg twice a day for 24 weeks

Trial Locations (2)

University of Pittsburgh, Pittsburgh

University of Michigan, Ann Arbor